Download our patient and provider guides. They contain all the information you and your doctor need to determine if Prequel is right for you.
Request more information about how Myriad’s prenatal screening options can benefit your patients.
Designed for patients of all ancestries and BMI, the Prequel Prenatal Screen is a non-invasive screen ordered by your healthcare provider. The results can help you learn about the health of your baby as early as 10 weeks into pregnancy.
Prequel delivers genetic insights about your baby’s health and development and can tell if a pregnancy is at an increased risk for a wide variety of conditions like Down, Edwards or Patau syndromes. The majority of pregnancies are at low risk for genetic conditions. In the case that a pregnancy is not, Prequel can help you prepare. For a full list of conditions, click here.
To learn more about the benefits of the Prequel Prenatal Screen, watch this informational video.
How non-invasive screening works
All it takes is a simple blood draw from your arm for analysis. With that blood sample, we can analyze small pieces of DNA from your baby’s placenta, called cell-free DNA. This allows us to determine the chance of your baby having a chromosome abnormality associated with a certain genetic condition. When screening with Prequel, there is no increased risk to you or your pregnancy, and results are available in 7 to 10 days.
The Prequel Prenatal Screen looks for a wide range of conditions that fall into the categories of common trisomies such as Down syndrome, sex chromosome differences, microdeletions and expanded aneuploidies.
Through advanced science and technology, Prequel delivers results to 99.9% of patients1 including those with twin and IVF pregnancies.
Prequel has the lowest screening failure rate in the industry, which means it’s less likely that you’ll need a repeat test or an unnecessary invasive diagnostic procedure.1
Your results regarding your level of risk will be simple to understand. You’ll also have on-demand access to our board-certified genetic counselors to ensure you understand your results.
The Prequel Prenatal Screen is a screening test, not a diagnostic test. This means it cannot give a definitive answer as to whether your pregnancy is affected by a chromosome condition.
Most expectant parents get reassuring results that their pregnancy is at low risk for chromosome abnormalities. If your screen indicates an elevated risk, your healthcare provider will discuss what this means with you. They may recommend a follow-up diagnostic procedure such as chorionic villus sampling (CVS) or amniocentesis to confirm positive screening results.
If your screening results indicate an elevated risk for a chromosomal condition, you may choose to pursue diagnostic testing to confirm. Regardless of this decision, you can create an informed plan to give your child the best possible start.
If you learn your child requires specialized care before birth, you can involve the right healthcare provider long before delivery.
You might want to seek out a specialized facility that is equipped to manage newborns with chromosome conditions.
You may simply want to talk with one of our patient educators or work with a support group to understand what could lie ahead.
In the case of high risk pregnancies, Prequel Prenatal Screen provides actionable results within 7 to 10 days.
Myriad is committed to providing patients with access to reliable and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.
Myriad believes in providing the highest quality screens for patients. From prenatal screens to precision medicine, our products are designed to give providers and patients the most reliable answer possible.
Foresight® Carrier Screen detects a couple’s risk of passing down serious, inheritable health conditions to their child to guide informed planning and preparation.
MyRisk® Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.